CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 871 enrolled
Drug / intervention
Not specified
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00521976
NCT00521976N/ACompleted

An Investigation of Activated Factor XII (Fxlla) as a Prognostic Marker.

Helse Stavanger HF·observational·Posted Aug 28, 2007·Updated Sep 29, 2021

In Brief

An observational study for Chest Pain and 3 related conditions. Completed, enrolled 871 participants across 1 site.

Detailed Summary

The main aim of this trial is to assess the long-term prognostic value of different types of Factor XIIa in an unselected, single center series of 871 chest pain patients admitted to the emergency unit, employing blood samples collected at admission. The second purpose of this study is to assess the incremental prognostic value of B-type natriuretic peptide (BNP) and high-sensitive C-reactive protein (hsCRP). A third purpose of this study is to evaluate the prognostic impact of the Omega-3 Index which is a measure of eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) relative to other fatty acids in the erythrocyte membrane.

Study Details

Study Typeobservational
Allocation--
Masking--
Primary Purpose--
CountriesNorway

Timeline

N/ACompletedFinished
2003200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedAug 28, 2007
Enrollment StartNov 1, 2002
Primary CompletionDec 1, 2005
TodayJul 2, 2026
Enrollment to primary: 3.1 yearsPosted 18.8 years ago